Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
Commentary|Videos|February 13, 2026
How MammaPrint Is Reshaping Treatment Decisions in HR+/HER2– Breast Cancer
Fact checked by: Kirsty Mackay
MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemotherapy use while protecting outcomes.
Advertisement
In this interview with Pharmacy Times, Lee Schwartzberg, MD, FACP, discusses how genomic profiling with MammaPrint and BluePrint helps identify patients with HR-positive, HER2-negative breast cancer who can safely avoid anthracycline-based chemotherapy without compromising outcomes. He explains how low- and ultralow-risk patients derive sufficient benefit from endocrine therapy alone, whereas high-risk patients benefit from more aggressive regimens, including anthracyclines. Schwartzberg highlights the importance of integrating genomic data with clinical and patient-specific factors to support personalized treatment decisions. He also emphasizes the critical role of pharmacists in multidisciplinary care teams, particularly in guiding testing decisions, educating patients, and managing chemotherapy-related toxicities.
Advertisement
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
4
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
5